NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
86.91
+0.23 (+0.27%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close86.68
Open86.65
Bid83.36 x 100
Ask83.41 x 1600
Day's Range86.61 - 87.57
52 Week Range72.67 - 94.19
Volume983,166
Avg. Volume1,444,301
Market Cap192.106B
Beta0.88
PE Ratio (TTM)26.74
EPS (TTM)3.25
Earnings DateN/A
Forward Dividend & Yield2.72 (3.14%)
Ex-Dividend Date2017-03-01
1y Target Est98.06
Trade prices are not sourced from all markets
  • How Celgene Hopes to Cash In on CAR-T
    Motley Fool20 hours ago

    How Celgene Hopes to Cash In on CAR-T

    Celgene's got more than one way to profit from this next-generation approach to beat cancer.

  • GlaxoSmithKline’s Revenues in 4Q17 Rose 1% Year-over-Year
    Market Realist2 days ago

    GlaxoSmithKline’s Revenues in 4Q17 Rose 1% Year-over-Year

    Must-Read Notes on GlaxoSmithKline’s 4Q17 EarningsGlaxoSmithKline’s revenues

  • How Cosentyx Resolves Enthesitis in Psoriatic Arthritis Patients
    Market Realist2 days ago

    How Cosentyx Resolves Enthesitis in Psoriatic Arthritis Patients

    Novartis: What Are the Major Growth Drivers for 2018? On November 14, 2016, Novartis (NVS) announced positive results from the Phase 3 pivotal study, FUTURE 1. This study highlighted the efficacy of Cosentyx in providing sustained benefit over three years in psoriatic arthritis patients.

  • Novartis’s Cosentyx May Emerge as a Leading Psoriasis Drug
    Market Realist2 days ago

    Novartis’s Cosentyx May Emerge as a Leading Psoriasis Drug

    Novartis: What Are the Major Growth Drivers for 2018? On January 16, 2018, Novartis (NVS) released data from its Phase 3b trial, CLARITY. This release highlighted the superiority of Cosentyx compared to Johnson & Johnson’s (JNJ) Stelara in clearing skin in patients with moderate to severe psoriasis at the end of 12 weeks and 16 weeks of therapy.

  • TheStreet.com2 days ago

    Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

    The Swiss pharmaceutical firm's U.S. generic pill business could attract as much as $1.6 billion, Reuters reported.

  • Novartis’s Cosentyx Emerged as Multi-Blockbuster Therapy in 2017
    Market Realist2 days ago

    Novartis’s Cosentyx Emerged as Multi-Blockbuster Therapy in 2017

    Novartis: What Are the Major Growth Drivers for 2018? In 4Q17, Novartis’s (NVS) Cosentyx reported global sales of $615.0 million, which is a year-over-year (or YoY) increase of 53.0% on a constant currency basis and 11.0% growth quarter-over-quarter. This growth was driven by the drug’s rapid uptake in all approved indications and in all geographies, with a focus on the US and Europe.

  • Reuters2 days ago

    Novartis readies to auction U.S. generic pills business - sources

    The move illustrates how the unit has diverged from the fortunes of the rest of Novartis' $10 billion (7.12 billion pounds) Sandoz generics and biosimilars division. The company has fared better in manufacturing hard-to-make generic drugs, such as injectables and inhalables, than it has with easier to produce pills. "It is a unique situation," new Novartis Chief Executive Vasant Narasimhan told investors and analysts during the company's fourth-quarter earnings call last month when asked about the future of the U.S. generic pills business.

  • Reuters2 days ago

    Novartis readies to auction U.S. generic pills business -sources

    Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday. The move illustrates how the unit has diverged from the fortunes of the rest of Novartis' $10 billion Sandoz generics and biosimilars division. The company has fared better in manufacturing hard-to-make generic drugs, such as injectables and inhalables, than it has with easier to produce pills.

  • Merck’s Human Vaccines Business in 4Q17
    Market Realist2 days ago

    Merck’s Human Vaccines Business in 4Q17

    Must-Read Notes on Merck & Co.’s 4Q17 and 2017 Earnings

  • How Did Pfizer’s Legacy Established Products Segment Perform in 2017?
    Market Realist2 days ago

    How Did Pfizer’s Legacy Established Products Segment Perform in 2017?

    Pfizer’s 2017 Performance in Review

  • Keytruda: Merck’s Largest Revenue Contributor in 4Q17
    Market Realist3 days ago

    Keytruda: Merck’s Largest Revenue Contributor in 4Q17

    Must-Read Notes on Merck & Co.’s 4Q17 and 2017 Earnings

  • 3 Tough Questions for Amgen
    Motley Fool3 days ago

    3 Tough Questions for Amgen

    How successful will Amgen be in the future? Its answers to these three questions provide insight.

  • InvestorPlace4 days ago

    3 Reasons to Be Bullish on Pfizer Inc. Stock

    Just a few weeks ago, Pfizer Inc. (NYSE:PFE) shares hit a 52-week high of $39.43. But of course, the recent correction in the equities markets has left a mark. During the period, PFE stock has lost about 11%.

  • Teva Stock Falls as Novartis Brings Another Copaxone Generic
    Zacks4 days ago

    Teva Stock Falls as Novartis Brings Another Copaxone Generic

    Teva's (TEVA) shares fall as Novartis launches the second generic version of the 40 mg formulation of Copaxone

  • CNW Group4 days ago

    IIROC Trade Resumption - NVS

    IIROC Trade Resumption - NVS

  • PR Newswire4 days ago

    IIROC Trade Resumption - NVS

    VANCOUVER , Feb. 14, 2018 /CNW/ - Trading resumes in: Company: Novicius Corp. CSE Symbol: NVS Resumption (ET): 9:30 AM IIROC can make a decision to impose a temporary suspension (halt) of trading in a ...

  • TheStreet.com5 days ago

    Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

    This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.

  • PR Newswire5 days ago

    IIROC Trading Halt - NVS

    VANCOUVER , Feb. 13, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Novicius Corp. CSE Symbol: NVS Reason: Pending News Halt Time (ET): 11:12 AM IIROC can make a decision to impose ...

  • CNW Group5 days ago

    IIROC Trading Halt - NVS

    IIROC Trading Halt - NVS

  • Analyzing Pfizer’s Ibrance and Xalkori after 2Q17
    Market Realist5 days ago

    Analyzing Pfizer’s Ibrance and Xalkori after 2Q17

    In 4Q17, Pfizer’s (PFE) Ibrance generated revenues of $716 million, which reflected ~11% growth on a YoY (year-over-year) basis and an 18% decline quarter-over-quarter. In the US market in 4Q17, Ibrance generated revenues of $777 million, which reflected ~27% growth on a YoY basis. In emerging markets in 4Q17, Ibrance reported revenues of $49 million—compared to $17 million in 4Q17.

  • Reuters5 days ago

    Novartis gains U.S. approval for delayed MS drug

    Novartis's (NOVN.S) Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. The U.S. Food and Drug Administration (FDA) approved a 40 milligrams per millilitre injection of the Novartis copy of Copaxone, Teva's (TEVA.N)(TEVA.TA) blockbuster medicine, Sandoz said in a statement on Tuesday. Israel-based Teva Pharmaceutical Industries began facing competition for its 40 mg version of Copaxone from Mylan (MYL.O) in October and has been bracing for more copycat versions of its bestselling drug.

  • MarketWatch5 days ago

    Teva shares drop 3% after rival generic product approved and launched

    Teva Pharmaceutical Industries Ltd. shares dropped 3% in premarket trade Tuesday after Novartis AG's Sandoz announced that the 40 mg dose of Glatopa, its generic for Teva's popular multiple sclerosis medication ...

  • Pfizer’s Sutent Generated Higher Revenues in 4Q17
    Market Realist5 days ago

    Pfizer’s Sutent Generated Higher Revenues in 4Q17

    How Did Pfizer’s Oncology Business Perform in 2017? 

  • Reuters5 days ago

    Novartis gains U.S. approval for delayed MS drug

    Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. The U.S. Food and Drug Administration (FDA) approved a 40 milligrams per millilitre injection of the Novartis copy of Copaxone, Teva's blockbuster medicine, Sandoz said in a statement on Tuesday. Israel-based Teva Pharmaceutical Industries began facing competition for its 40 mg version of Copaxone from Mylan in October and has been bracing for more copycat versions of its bestselling drug.

  • Bristol-Myers Squibb’s Oncology Portfolio in 4Q17
    Market Realist6 days ago

    Bristol-Myers Squibb’s Oncology Portfolio in 4Q17

    Must-Read Notes on Bristol-Myers Squibb’s 4Q17 and 2017 Earnings